‘Small Biotech Exception’ From Medicare Price Negotiation Granted To Four Drugs For 2026

 
• By Cathy Kelly
  
lab research
CMS Criteria For Decisions On Applications Still To Come • Source: Shutterstock

More from Market Access

More from Pink Sheet